Kassem N, Elswefy D, Eman N, Mogy M, Moussa M, Ali R (2014) Prognostic value of 13q14 deletion and IgH 14q32 rearrangement by interphase fluorescence in situ hybridization in patients with multiple myeloma. J Appl Hematol 5(4):123–146
Article
Google Scholar
Udupa CBK, Udupa KS, Pai A, Sherigar P (2020) Cytogenetics and Revised International Staging System (R-ISS): risk stratification in multiple myeloma—a retrospective study in Indian Population. Iran J Pathol 15(3):182–188. https://doi.org/10.30699/ijp.2020.105128.2078
Article
PubMed
PubMed Central
Google Scholar
Hamdaoui H, Benlarroubia O, Boujmia O, MossafaH OuldimK, BelkhayatA SI, Benrahma H, Dehbi H, Chegdani F (2016) Cytogenetic and FISH analysis of 93 multiple myeloma Moroccan patients. Molecular genetics and Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma genomic medicine. Mol Genet Genomic Med 8(9):1363–1378
Google Scholar
Sonneveld P, Avet-Loiseau H, Lonial S (2016) Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 127:2955–2962
Article
CAS
Google Scholar
Barwick BG, Neri P, Bahlis NJ (2019) Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. Nat Commun 10(1):1911. https://doi.org/10.1038/s41467-019-09555-6
Article
CAS
PubMed
PubMed Central
Google Scholar
Palumbo A, Loiseau HA, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie B, Anderson KC, Sonneveld P, Miguel J, Cavo M, Rajkumar SV, Moreau P (2015) Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol 33(26):2863–2869
Article
CAS
Google Scholar
Rajkumar SV (2020) Multiple myeloma: 2020 update on diagnosis, risk-stratification, and management. Am J Hematol 95(5):548–567
Article
CAS
Google Scholar
Prabhala RH (2016) Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma. Leukemia 30(6):379–389
Article
CAS
Google Scholar
Cauwelier B, Dastugue N, Cools J, Poppe B, Herens C, Paepe AD, Hagemeijer A, Speleman F (2006) Molecular cytogenetic study of 126 unselected T-ALL cases reveals high incidence of TCRβ locus rearrangements and putative new T-cell oncogenes. Leukemia 20(2):1238–1244
Article
CAS
Google Scholar
Khan T, Khan S, Stefanacci R (2017) Multidisciplinary management of multiple myeloma in older adults. J Clin Pathways 3(6):45–48
Google Scholar
Sidana S, Jevremovic D, Ketterling RP, Tandon N, Dispenzieri A, Gertz MA, Greipp PT, Baughn LB, Buadi FK, Lacy MQ, Morice W, Hanson C, Timm M, Dingli D, Hayman SR, Gonsalves WI, Kapoor P, Kyle RA, Leung N, Go RS, Lust JA, Rajkumar SV, Kumar SK (2019) Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method. Am J Hematol 94(4):424–430
Article
CAS
Google Scholar
AlHashmi H, Al Dayel A, Soliman D, Al Sayegh M, AbdulJalil O, Al Anezi K, Al Matrok A, Kaloyanidis P, Al Saber A, Kamel M, Raslan H (2019) Hyperdiploidy is a positive prognostic factor for progression free survival in multiple myeloma with high and intermediate risk cytogenetics. Health Sci 12(5):590
Google Scholar
White BS, Lanc I, O’Neal J, Gupta H, Fulton RS, Schmidt H, Fronick C, Belter EA, Fiala M, King J, Ahmann GJ, DeRome M, Mardis ER, Vij R, DiPersio JF, Levy J, Auclair D, Tomasson MH (2018) A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8(4):31–35
Google Scholar
Hamdaoui H, Benlarroubia O, Boujmia OK, Mossafa H, Ouldim K, Belkhayat A, Smyej I, Benrahma H, Dehbi H, Chegdani F (2020) Cytogenetic and FISH analysis of 93 multiple myeloma Moroccan patients. Molecular genetics and metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma genomic medicine. Mol Genet Genomic Med 8(9):1363–1378
Article
Google Scholar
Khallaf SM, Yousof EA, Ahmed EH, Mansor SG, Mohamed HO, Elgammal S, Moeen SM, Sayed DM (2020) Prognostic value of CD56 expression in multiple myeloma. Res Oncol 16(1):6–10
Google Scholar
Warnnissorn N, Treetipsatit J, Limvorapitak W (2020) The cut-offs for kappa/lambda ratio in bone marrow immunohistochemistry for the diagnosis of multiple myeloma. Hematol J 25(1):292–298
CAS
Google Scholar
Cisse MM, Mahamat Abderraman G, Fall K, Tall A, Faye A, Hamat I, Nestor Z, Nankeu K, Abou SY, Faye M, Elhaj Fary KA, Niang A, Diouf B (2018) Prognostic factors of renal impairment in multiple myeloma in Senegal. Nephrol Urol 2(3):1–12
Google Scholar
Zeng T, Zhou L, Xi H, Fu W, Du J, Zhang C, Jiang H, Hou J (2015) Multiple myeloma patients at various cytogenetic risks benefit differently from autologous stem cell transplantation as a consolidation therapy. Stem Cells Int 9(2):70–77
Google Scholar
Amare PS, Jain H, Nikalje S, Sengar M, Menon H, Inamdar N, Subramanian PG, Gujral S, Shet T, Epari S, Nair R (2016) Observation on frequency and clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India. Indian J Med Res 144(4):536
CAS
Google Scholar
Barilà G, Bonaldi L, Grassi A, Martines A, Liço A, Macrì N, Nalio S, Pavan L, Berno T, Branca A, Calabretto G, Carrino M, Teramo A, Manni S, Piazza F, Semenzato G, Zambello, (2020) Identification of the true hyperdiploid multiple myeloma subset by combining conventional karyotyping and FISH analysis. Blood Cancer J 10(2):18–65
Article
Google Scholar
Mellors PW, Binder M, Ketterling RP, Greipp PT, Baughn LB, Peterson JF, Jevremovic D, Pearce KE, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa YL, Fonder A, Hobbs M, Kourelis T, Warsame R, Lust JA, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SV (2020) Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Adv 4(10):2236–2244
Article
Google Scholar
Tandon N, Sidana S, Rajkumar SV, Gertz MA, Buadi F, Lacy M, Kapoor P, Gonsalves WI, Dispenzieri A, Kourelis T, Warsame R, Dingli D, Fonder A, Hayman SR, Hobbs M, Hwa Y, Kyle R, Leung N, Go R, Lust J, Russell SJ, Shaji K (2019) Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma. Blood Adv 3(5):744–750
Article
CAS
Google Scholar
Benavides IJ, de Ramón C, Gutiérrez NC (2021) Genetic abnormalities in multiple myeloma prognostic and therapeutic implications. Cells 10(2):336–346
Article
Google Scholar
Jakubowiak A, Siegel D, Martin T (2013) Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia 27(2):2351–2356
Article
CAS
Google Scholar
Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK (2019) Impact of acquired del(17p) in multiple myeloma. Blood Adv 3(13):1930–1938
Article
CAS
Google Scholar